An ongoing industry-sponsored multi-centered phase II clinical trial was recently initiated to test IDO vaccinations in combination with pembrolizumab as a first-line treatment for patients with NSCLC (NCT03562871). The gene discussed is IDO1; the disease is non-small cell lung carcinoma.